145 related articles for article (PubMed ID: 26230362)
21. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Banerjee SN; Tang M; O'Connell RL; Sjoquist K; Clamp AR; Millan D; Nottley S; Lord R; Mullassery VM; Hall M; Gourley C; Bonaventura T; Goh JC; Sykes P; Grant PT; McNally O; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Edmondson RJ; Friedlander M;
Gynecol Oncol; 2021 Oct; 163(1):72-78. PubMed ID: 34412908
[TBL] [Abstract][Full Text] [Related]
22. Hormone therapy in ovarian granulosa cell tumors: a systematic review.
van Meurs HS; van Lonkhuijzen LR; Limpens J; van der Velden J; Buist MR
Gynecol Oncol; 2014 Jul; 134(1):196-205. PubMed ID: 24713548
[TBL] [Abstract][Full Text] [Related]
23. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Lavrenkov K; Man S; Geffen DB; Cohen Y
Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
[TBL] [Abstract][Full Text] [Related]
24. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
25. [Granulosa cell tumor of the ovary: retrospective study of 17 cases].
Rebstock LE; Leufflen L; Leroux A; Harter V; Verhaeghe JL; Marchal F
Gynecol Obstet Fertil; 2014 May; 42(5):331-3. PubMed ID: 24394321
[TBL] [Abstract][Full Text] [Related]
26. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
27. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
28. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
Mamounas EP; Lembersky B; Jeong JH; Cronin W; Harkins B; Geyer C; Wickerham DL; Paik S; Costantino J; Wolmark N
Clin Breast Cancer; 2006 Dec; 7(5):416-21. PubMed ID: 17239269
[No Abstract] [Full Text] [Related]
29. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Nabholtz JM
Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
[TBL] [Abstract][Full Text] [Related]
30. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Aihara T; Yokota I; Hozumi Y; Aogi K; Iwata H; Tamura M; Fukuuchi A; Makino H; Kim R; Andoh M; Tsugawa K; Ohno S; Yamaguchi T; Ohashi Y; Watanabe T; Takatsuka Y; Mukai H
Breast Cancer Res Treat; 2014 Nov; 148(2):337-43. PubMed ID: 25318924
[TBL] [Abstract][Full Text] [Related]
31. Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.
Serkies K; Abacjew-Chmyłko A; Wieczorek-Rutkowska M; Pęksa R
Ginekol Pol; 2018; 89(11):607-610. PubMed ID: 30508212
[TBL] [Abstract][Full Text] [Related]
32. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Pritchard KI
Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
34. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Bowman A; Gabra H; Langdon SP; Lessells A; Stewart M; Young A; Smyth JF
Clin Cancer Res; 2002 Jul; 8(7):2233-9. PubMed ID: 12114425
[TBL] [Abstract][Full Text] [Related]
35. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
36. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
Pink D; Lindner T; Mrozek A; Kretzschmar A; Thuss-Patience PC; Dörken B; Reichardt P
Gynecol Oncol; 2006 Jun; 101(3):464-9. PubMed ID: 16368128
[TBL] [Abstract][Full Text] [Related]
37. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
38. Emerging role of aromatase inhibitors in the treatment of breast cancer.
Harvey HA
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
[TBL] [Abstract][Full Text] [Related]
39. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study.
Papadimitriou CA; Markaki S; Siapkaras J; Vlachos G; Efstathiou E; Grimani I; Hamilos G; Zorzou M; Dimopoulos MA
Oncology; 2004; 66(2):112-7. PubMed ID: 15138362
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological prognostic factors of adult granulosa cell tumor of the ovary--a study of 37 cases.
Mehta H; Trivedi P; Parikh B; Shukla K; Shah MJ
Indian J Pathol Microbiol; 2005 Oct; 48(4):439-43. PubMed ID: 16366090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
